Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03124004
Other study ID # NOADB_debridement
Secondary ID
Status Recruiting
Phase N/A
First received March 30, 2017
Last updated April 18, 2017
Start date August 15, 2016
Est. completion date November 15, 2018

Study information

Verified date April 2017
Source University of Trieste
Contact Roberto Di Lenarda, Prof.
Phone 0403992254
Email rdilenarda@units.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Direct Oral Anticoagulants were recently approved for medical treatment of several condition such as, non valvular atrial fibrillation, deep venous thrombosis, and others, substituting sometimes the conventional oral anticoagulants. The aim of the present study is to observe the possible difference in intra-operative and post-operative bleeding events for periodontal debridement.


Description:

Many protocols of drug suspension for surgical procedure has been designed, since the introduction of anticoagulant or antiplatelet medications. Nowadays it is not certain if suspension could give more costs than benefits for the clinical procedure itself. With the recent development of the Direct Oral Anticoagulant it is still unclear whether these medications might bring more bleeding events in the intra-operative and post-operative phase after periodontal causal therapy, equal to, or more than Oral Anticoagulant Therapy. The purpose of this study is to assess the degree of intra- and post-operative bleeding complication between direct oral anticoagulant therapy patients and Oral Anticoagulant Therapy patients for periodontal debridement.


Recruitment information / eligibility

Status Recruiting
Enrollment 128
Est. completion date November 15, 2018
Est. primary completion date November 15, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years and older
Eligibility Direct Oral Anticoagulant

Inclusion Criteria:

1. Male and female patients at 20 or more years of age.

2. Healthy patients (= American Society of Anesthesiologists 3).

3. Regular oral anticoagulant therapy assumed from at least 3 months with the following molecula: Dabigatran (PRADAXA), Rivaroxaban (XARELTO), Apixaban (ELIQUIS), Edoxaban (LIXIANA).

4. Indication for extraction of a single tooth.

5. No other contraindications for tooth extraction.

6. Accepted platelet count within 7 days prior to the procedure has to be > 50000 mg/dl.

7. Signed informed consent.

Exclusion Criteria:

1. Smoke > 10 cigarettes per day.

2. Assumption of any antiplatelet medication.

3. Assumption of Heparin medication.

4. Assumption of oral anticoagulant medications (Warfarin, Coumadin).

5. Wash-out period after antiplatelet or Heparin medication at least 15 days.

6. Assumption of food or drugs that may alter direct oral anticoagulant blood values.

7. Uncontrolled Hypertension.

8. Uncontrolled Diabetes

9. Chronic Hepatitis and/or reduction of hepatic function

10. Coagulopathy (in excess of defect)

11. Anamnestically known intolerance to one of the drugs applied or to their ingredients or to drugs of similar chemical structure.

12. Head and neck radiotherapy (previous 10 years).

13. Chemotherapy (previous 2 years).

14. Participation of the patient in another clinical trial within the last four weeks before enrollment in this trial.

15. Incapability of assessing essence and possible consequences of the trial (e.g. alcoholism).

16. Pregnant or breastfeeding women.

17. Evidence suggesting that the patient is not likely to follow the study protocol (e.g. lack of compliance).

Oral Anticoagulant Therapy

Inclusion Criteria:

1. Male and female patients at 20 or more years of age.

2. General health status (< American society of anesthesiologist a 3).

3. Regular oral anticoagulant therapy assumed from at least 3 months with the following molecula: Warfarin (COUMADIN), acenocoumarol (SINTROM).

4. Indication for extraction of a single tooth.

5. No contraindications for tooth extraction.

6. Accepted platelet count within 7 days prior to the procedure has to be > 50000 mg/dl.

7. International Normalized Ratio measured within 7 days prior to the procedure should between 2.0 and 3.0.

8. No diet changes within the week before blood sampling (avoiding interacting food)

9. Signed informed consent.

Exclusion Criteria:

1. Smoke > 10 cigarettes per day.

2. Assumption of any antiplatelet medication.

3. Assumption of any Heparin medication.

4. Assumption of any direct oral anticoagulant medication.

5. Uncontrolled Hypertension.

6. Uncontrolled Diabetes.

7. Chronic Hepatitis and/or reduction of hepatic function

8. Coagulopathy (in excess of defect)

9. Wash-out period after antiplatelet or Heparin medication at least 15 days.

10. Anamnestically known intolerance to one of the drugs applied or to their ingredients or to drugs of similar chemical structure.

11. Assumption of food or drugs that may alter oral anticoagulant blood values.

12. Head and neck radiotherapy (previous 10 years).

13. Chemotherapy (previous 10 years).

14. Participation of the patient in another clinical trial within the last four weeks before enrollment in this trial.

15. Incapability of assessing essence and possible consequences of the trial (e.g. alcoholism).

16. Pregnant or breastfeeding women.

17. Evidence suggesting that the patient is not likely to follow the study protocol (e.g. lack of compliance).

Study Design


Intervention

Procedure:
periodontal debridement
with ultrasonic device supragingival and subgingival full-mouth debridement is provided

Locations

Country Name City State
Italy Clinica Odontoiatrica e Stomatologica Trieste

Sponsors (1)

Lead Sponsor Collaborator
University of Trieste

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other oral health status examination of the oral cavity, registration of periodontal indices 1 week before
Other cardiological assessment registration of the Atrial Fibrillation Stroke Risk score 1 week before
Other bleeding risk assessment registration of the Score for Major Bleeding Risk score 1 week before
Primary intra-operative bleeding intra-operative bleeding is registered as follows: mild if stopped in 20 seconds; medium: if stopped after not more than one minute; severe: if not stopped. 30 minutes
Secondary post-operative bleeding events a questionnaire is given to the patient to register post-operative bleeding events 1 week
See also
  Status Clinical Trial Phase
Completed NCT04712630 - Non-Incised Papillae Surgical Approach (NIPSA) With and Without Graft N/A
Recruiting NCT03997552 - NIPSA Versus Marginal Approach by Palatal Incision and MIST in Periodontal Regeneration N/A
Completed NCT04478864 - Knowledge, Practice and State of Periodontal Health
Completed NCT03507868 - YKL-40 and IL-6 Levels in Periodontal Disease
Completed NCT05720481 - Impact of Periodontal Treatment on Growth Differentiation Factor-15 Levels N/A
Recruiting NCT06052150 - Oral Health In Cirrhosis of the Liver (ORACLE)
Recruiting NCT06025955 - Evaluation of Outcomes of Minimally Invasive Non- Surgical Versus Surgical Therapy in Furcation Involvement. N/A
Recruiting NCT03510702 - SCREENING OF EPIGENETIC BIOMARKERS (miRNAs) IN THE GINGIVAL SULCUS
Completed NCT05631600 - Manuka Honey as an Adjunct to Non-surgical Periodontal Therapy: Clinical Study Phase 2/Phase 3
Active, not recruiting NCT05068778 - Development of an AI App to Improve Compliance in Periodontal Maintenance Patients
Not yet recruiting NCT05178563 - Mechanisms of Acute Inflammation Following Periodontal Treatment N/A
Recruiting NCT06086821 - Clinical Relevance of Different Time of Periodontal Re-evaluation N/A
Recruiting NCT06224699 - Toothpaste With Sodium Carbonate in Patients With Gingivitis N/A
Not yet recruiting NCT05721313 - Vital Root Amputation in Molars With Advanced Periodontal Furcation Involvement: a Preliminary Study N/A
Completed NCT06040944 - Antipsychotic Induced Hyperprolactinemaia as Risk Factor for Periodontitis in Schizophrenic Patients
Completed NCT06306937 - Serum Levels of Vitamin D and IL8 in Patients With Periodontitis
Recruiting NCT04669717 - Antibiotics as Adjuncts to Periodontal Therapy:Pharmacokinetic Considerations and Dosing Strategies Phase 4
Completed NCT05576142 - Oral Findings in Pediatric Patients With Allergic Rhinitis and/or Asthma
Completed NCT04017078 - Assessment of Carotid Artery Calcifications
Not yet recruiting NCT03588507 - Clinical and Radiographic Evaluation of PPF With or Without NCHA Bone in Treatment of Intrabony Defects N/A